July 10, 2018

Students Impacted by Epilepsy Use Scholarships to Become Agents of Change Across the US

Citizens United for Research in Epilepsy (CURE) and Lundbeck have announced the newest cohort of Education Enrichment Fund (EEF) Scholars for 2018. These 10 new scholars have all been personally impacted by epilepsy and, collectively, will receive nearly $50,000 to advance their education while bringing greater awareness to epilepsy.

The EEF Scholarships—made possible by generous support from Lundbeck—award a one-time scholarship (up to $5,000) to those living with epilepsy, or for family members and caregivers of those impacted by the disease. The scholarship, which is in its third year, covers tuition, books, and academic materials and supports coursework advancing personal knowledge in research, health education and advocacy in relation to epilepsy.

“As a patient-centered and research driven organization, CURE greatly appreciates Lundbeck’s generous support of the Education Enrichment Fund Scholars Program,” said Stacey Pigott, Chair of CURE’s Research Committee. “This year’s recipients are all incredibly deserving with their personal connection to epilepsy and shared goal of furthering their education to enact positive change within the broader epilepsy community.”

One scholar, after serving as a nurse for seven years in the U.S. Army, was diagnosed with epilepsy caused by a brain tumor. Her personal battle towards recovery has led her to pursue a career as a Psychiatric Mental Health Nurse Practitioner.

Another scholar has spent ten years battling for her son who was diagnosed with epilepsy at the age of four. Her triumphs and tragedies have motivated her to pursue a career as a Family Nurse Practitioner so she can advocate for others who are battling this disorder.

Other awardees include an aspiring pediatric neurologist seeking to combat the effects of epilepsy he has witnessed in his older brother; a student living with epilepsy himself and striving to become a neurologist; and a teacher in the peace corps seeking to advance epilepsy research to treat not only her own disorder, but the disorder of the students in her classroom.

“This is the third round of Education Enrichment Fund Scholars and, once again, I am amazed at the recipients’ passion, hopefulness and determination to make a difference in the lives of others who are living with epilepsy,” said Lorena Di Carlo, Vice President & General Manager, Neurology, at Lundbeck. “This initiative has taught us so much about the strength of the epilepsy community, and we are proud to be a part of it.”

Launched in 2016 with just three scholars, the EEF Scholarship program has more than tripled in 2018 and has supported nearly 20 scholars since the program’s inception.
2018 winners include:

 

Click to learn more about each scholar.

###

About CURE

The mission of Citizens United for Research in Epilepsy (CURE) is to find a cure for epilepsy, by promoting and funding patient-focused research.  Since its inception in 1998, CURE has raised over $50 million to advance its goal of no seizures and no side effects. To date, CURE has awarded more than 220 cutting-edge research projects in 15 countries around the world. CURE is the leading nongovernmental agency fully committed to funding research in epilepsy.

For information about CURE, please visit our website at www.CUREepilepsy.org or contact us at info@CUREepilepsy.org.

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in psychiatric and neurological disorders. For more than 70 years, we have been at the forefront of research within neuroscience. Our key areas of focus are depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
An estimated 700 million people worldwide are living with psychiatric and neurological disorders and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with psychiatric and neurological disorders — we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind.

Our approximately 5,000 employees in more than 50 countries are engaged in the entire value chain throughout research, development, production, marketing and sales. Our pipeline consists of several late-stage development programs and our products are available in more than 100 countries. Our research center is based in Denmark and our production facilities are located in Denmark, France and Italy. Lundbeck generated revenue of DKK 17.2 billion in 2017 (EUR 2.3 billion; USD 2.6 billion).

In the U.S., Lundbeck employs nearly 1,000 people focused solely on accelerating therapies for brain disorders. With a special commitment to the lives of patients, families and caregivers, Lundbeck U.S. actively engages in hundreds of initiatives each year that support our patient communities. For additional information, we encourage you to visit our corporate site at www.lundbeck.com/us and connect with us on Twitter at @LundbeckUS.

Related News